Simple Summary Metronomic chemotherapy, a continuous administration of a lowered dose
of drugs without long breaks, is currently considered an alternative approach for the …

Over 15 years ago, low-dose metronomic chemotherapy was shown to induce disease
control in patients with advanced-stage breast cancer with a lower incidence of adverse …

Low-dose metronomic (LDM) chemotherapy, the frequent and continuous use of low doses
of conventional chemotherapeutics, is an emerging alternative to conventional …

Conventional cytotoxic anticancer chemotherapeutic drugs were developed with the intent of
treating cancer by direct killing or inhibition of growth of cycling tumour cells. Recently …

Anticancer drugs typically have a narrow therapeutic index, often producing acute toxicity at
dosages similar to those required for therapeutic efficacy. These toxicities may be severe …

Since its inception in 2000, metronomic chemotherapy has undergone major advances as
an antiangiogenic therapy. The discovery of the pro-immune properties of chemotherapy …

Several anticancer drugs display characteristics that make them suitable candidates for
therapeutic drug monitoring (TDM), including substantial pharmacokinetic variability and a …

Tumour endothelium is a new target for anticancer treatments. Proliferating endothelial cells
from the tumour, even if qualitatively different from those of blood vessels in the normal …

The translation of advances in cancer biology to drug discovery can be complicated by
pharmacokinetic variation between individuals and within individuals, and this can result in …

Metronomic dosing of chemotherapy—defined as frequent administration at lower doses—
has been shown to be more efficacious than maximum tolerated dose treatment in …